Organon and Medarex announce biotherapeutics development agreement

21-May-2007

Organon, the human health care business unit of Akzo Nobel, and Medarex, Inc. announced that they have entered into a collaborative agreement to develop and potentially commercialize fully human antibody therapeutics for the treatment of cancer and auto-immune disorders, utilizing Medarex's UltiMAb Human Antibody Development System® and Organon's expertise in drug discovery and development.

Under the terms of the agreement, Organon and Medarex plan to share development and commercialization responsibilities on any antibody-based therapeutics resulting from this collaboration, and to share revenues generated from the sale of such therapeutic products. Financial terms were not disclosed.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances